Rani Therapeutics Holdings (RANI) Income towards Parent Company (2020 - 2026)

Rani Therapeutics Holdings' Income towards Parent Company history runs 7 years deep, the most recent figure standing at -$10.4 million for Q1 2026.

• On a quarterly basis, Income towards Parent Company rose 18.72% year-over-year to -$10.4 million in Q1 2026; TTM through Mar 2026 was -$42.2 million, a 29.57% increase from a year earlier, with the FY2025 full-year figure at -$116.5 million, down 105.96% from the prior year.
• Income towards Parent Company declined to -$10.4 million in Q1 2026 per RANI's latest filing, from -$8.6 million in the prior quarter.
• Across five years, Income towards Parent Company topped out at -$8.6 million in Q4 2025 and bottomed at -$18.7 million in Q2 2023.
• The 5-year median for Income towards Parent Company is -$14.8 million (2024), against an average of -$14.6 million.
• Across the five-year window, Income towards Parent Company slumped 191.08% in 2022 and surged 45.13% in 2025, its largest moves.
• Year by year, Income towards Parent Company stood at -$17.4 million in 2022, then increased by 19.09% to -$14.1 million in 2023, then retreated by 11.86% to -$15.7 million in 2024, then surged by 45.13% to -$8.6 million in 2025, then decreased by 20.02% to -$10.4 million in 2026.
• Per Business Quant, the three latest RANI Income towards Parent Company figures stand at -$10.4 million (Q1 2026), -$8.6 million (Q4 2025), and -$12.0 million (Q3 2025).